Issue of Equity

RNS Number : 0304Q

Immupharma PLC

24 February 2016

 

                                                                                                                                                              24 FEBRUARY 2016

ImmuPharma PLC

Issue of Equity

Successful placing provides funding for completion of Phase III Lupuzor™ Trial

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the issue and allotment of 30,302,217 new ordinary shares of 10 pence each ("New Ordinary Shares"), raising £7.7 million in connection with the Placing and Subscription, as announced on 5 February 2016 (the "Placing and Subscription Announcement").

Furthermore, as outlined in the Placing and Subscription Announcement, the Company has applied to HM Revenue and Customs to receive VCT Advance Assurance and / or EIS Advance Assurance but, as of the date of this announcement, the Advance Assurances have not yet been received. The issue of any EIS Shares and the VCT Shares within the Placing, amounting to 2,856,539 Ordinary Shares  which would raise a further £0.7 million for the Company (raising in aggregate £8.4 million, as announced in the Placing and Subscription Announcement), is conditional upon the Advance Assurances being obtained by not later than 23 March 2016.  The Company intends to issue and allot the EIS Shares and VCT Shares provided the Advance Assurances are received by that date.   A further update will be provided in due course.

Application will be made to the London Stock Exchange plc for the admission of the 30,302,217 New Ordinary Shares to trading on AIM. Admission is expected to take place at 8 a.m. on 25 February 2016 (or such later date as Panmure Gordon and the Company may agree, being not later than 8 a.m. on 24 March 2016) at which time the Placing and Subscription will become unconditional (save with regard to the EIS Shares and the VCT Shares). Dealings in the New Ordinary Shares on AIM will commence at the same time. The New Ordinary Shares will be issued credited as fully paid and will be identical to, and rank pari passu in all respects with, the Existing Ordinary Shares, including the right to all dividends and other distributions declared, made or paid in respect of the Existing Ordinary Shares following the date of Admission.

Following the issue of the New Ordinary Shares referred to above, ImmuPharma will have 118,924,680 Ordinary Shares in issue. No Ordinary Shares are held in treasury. Shareholders may use the above figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under section 5 of the FCA's Disclosure and Transparency Rules.

For further information please see the Company's website, www.immupharma.org, or contact:

ImmuPharma plc Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations	+ 44 (0) 20 7152 4080 + 44 (0) 7721 413496 [e-mail]
Panmure Gordon (Financial Adviser, Nominated Adviser & Broker) Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking	[phone]

All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on 5 February 2016.

 

END

 

 

IOEEAAALADLKEFF